Back to blog

AstraZeneca Changes U.S. Exchange: What Does It Mean for European Investors?

At the beginning of the week, shares of pharmaceutical giant AstraZeneca rose by 1.5%* on the London Stock Exchange. The reason? It was a reaction to the planned transfer of trading from Nasdaq via American Depositary Receipts directly to the New York Stock Exchange (NYSE). In response, investors in Europe began to wonder: “What would such a move mean for my portfolio?”

AstraZeneca Changes U.S. Exchange: What Does It Mean for European Investors?

Harmonization

Chairman Michel Demare emphasized in an official statement that the new harmonized listing model is primarily intended to support the company’s long-term strategy of sustainable growth and access to global investors. The statement further noted that AstraZeneca remains firmly anchored in the United Kingdom—with its headquarters, tax residency, and primary listings in London and Stockholm. It can therefore be said that the transfer within the United States does not mean an escape from London but rather the company’s effort to expand its international investor base.

azn_ln

Source: Trading Economics*

London Under Pressure

The moves of major companies, however, evoke a broader trend. In recent years, London has faced a significant outflow of prestigious names—Unilever moved its activities to Amsterdam, while Glencore and Ashtead are considering similar steps. This is why news of a possible departure of AstraZeneca from London was perceived with concern. Based on current information, however, these concerns have been partially alleviated, though it is also clear that competition between stock exchanges is tougher than ever.

Political Dimension

The traditional political pressure from the U.S. is also not negligible. President Donald Trump repeatedly warned pharmaceutical companies that if they do not increase investment and production in the United States, they could face high tariffs. The move to list on the NYSE can therefore also be seen as a diplomatic gesture—a way to stay closer to U.S. investors and regulators without the company losing its European identity.

In addition, at the beginning of September the company decided to cancel its planned £200 million expansion of its research center in Cambridge, which at the same time signals that even in the United Kingdom the business environment is not without problems.

What Comes Next?

From a European investor’s perspective, AstraZeneca’s move to the NYSE is primarily about practical consequences. Expanding access to U.S. capital can support the company’s long-term growth, which may also be reflected in the performance of its shares on the London Stock Exchange. At the same time, however, this step is a reminder that London is no longer an automatic center for global companies, and the competitive pressure from the U.S. and the EU will continue to increase over time.[1]

*Past performance is not a guarantee of future results.

[1] Forward-looking statements represent assumptions and current expectations, which may not be accurate, or are based on the current economic environment, which may change. These statements do not guarantee future performance. By their nature, forward-looking statements involve risk and uncertainty, as they relate to future events and circumstances that cannot be predicted, and actual developments and results may differ materially from those expressed or implied in any forward-looking statements.

Disclaimer! This marketing material is not and must not be understood as investment advice. Past performance is not a guarantee of future results. Investing in foreign currency may affect returns due to fluctuations. All securities transactions may result in both profits and losses. Forward-looking statements represent assumptions and current expectations, which may not be accurate, or are based on the current economic environment, which may change. These statements do not guarantee future performance. CAPITAL MARKETS, o.c.p., a.s. is an entity regulated by the National Bank of Slovakia.

Sources:

https://www.investing.com/news/stock-market-news/astrazeneca-to-list-directly-on-nyse-while-keeping-uk-listing-shares-up-4259703
https://www.theguardian.com/business/2025/sep/29/astrazeneca-plans-new-york-stock-exchange-listing-but-isnt-quitting-london

Read more

The New Nvidia and Intel Deal: What Investors Should Take Away!

The New Nvidia and Intel Deal: What Investors Should Take Away!

The tech world was rocked by the news of a groundbreaking alliance between Nvidia, currently the most valuable company in the world, and Intel, the historically iconic chip manufacturer. From an investment perspective, this is a collaboration that has the potential to significantly strengthen the intrinsic value of both companies by expanding their product portfolios into highly promising areas.[1]

Broadcom: From Loss to Billion-Dollar AI Contracts

Broadcom: From Loss to Billion-Dollar AI Contracts

Most recently among the technology giants, Broadcom released its quarterly results, confirming that it undoubtedly belongs among the main winners of the artificial intelligence era. Last year, due to tax obligations stemming from the transfer of intellectual property to the U.S., the company recorded a significant one-off loss, but it has once again managed to return to high profitability – something that pleased investors as well. After the results were published, the stock rose by 16%.*

Google Stock Near All-Time High – Will Earnings Fuel More Gains?

Google Stock Near All-Time High – Will Earnings Fuel More Gains?

During the second quarter, Google once again proved why it ranks among the technological leaders. With economic results that not only exceeded analysts' expectations, but above all showed the ability to move forward even in an extremely competitive environment, the company continues to represent a promising player in the investment portfolio in the eye of investors. In addition, the stock price is still below the absolute high, which is a much better entry into the market than in the case of stocks that are at their peak.*

Figma Eyes IPO – Should Adobe Be Concerned?

Figma Eyes IPO – Should Adobe Be Concerned?

As part of the initial public offerings, another promising company appears on the horizon. Figma, an innovative design design platform, is gearing up for an IPO that could generate up to $1 billion in revenue. The projected share price is in the range of $25 to $28, which could bring the final value up to $16 billion. [1] Figma is thus preparing for one of the biggest steps in its history, which will subsequently be available to retail investors. What is its advantage over the competition?